SEC Form 4 · accession 0000899243-18-019717
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lesley Ann Calhoun
Officer — See Remarks
Period of report
Jul 6, 2018
Accepted (ET)
Jul 10, 2018 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2018 | M | 1,000 | $22.00 | A | 1,388 | D | |
| Common Stock | Jul 6, 2018 | S | 1,000 | $44.005 | D | 388 | D | |
| Common Stock | Jul 9, 2018 | M | 2,295 | $22.00 | A | 2,683 | D | |
| Common Stock | Jul 9, 2018 | S | 2,295 | $44.274 | D | 388 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $22.00 | Jul 6, 2018 | M | 1,000 | D | — | Aug 14, 2026 | Common Stock | 1,000 | 29,000 | D |
| Stock Option (Right to Buy)F1 | $22.00 | Jul 9, 2018 | M | 2,295 | D | — | Aug 14, 2026 | Common Stock | 2,295 | 26,705 | D |
Explanation of responses
- F1The Stock Option becomes exercisable with respect to 1/4th of the underlying shares on August 15, 2017 and with respect to an additional 1/12th of the underlying shares each quarter thereafter until fully vested on August 15, 2020, subject to the Reporting Person's continuous service with the Issuer. The Stock Option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Remarks
Vice President, Finance and Principal Accounting Officer